Innovent Announces First Participant Dosed in Phase 1 Clinical Study of IBI333 (VEGF-A/VEGF-C Bispecific Fusion Protein) in Patients with Neovascular Age-related Macular Degeneration

/PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Related Keywords

China ,Peking ,Beijing ,Hong Kong ,Suzhou ,Jiangsu ,Innovent Biologics ,Youxin Chen ,Adimab Incyte ,Eli Lilly ,Clinical Development Of Innovent ,Md Anderson Cancer Center ,Union Medical College Hospital ,Lancet Glob Health ,Innovent Biologics Inc ,Peking Union Medical College Hospital ,Principal Investigator ,Lei Qian ,Vice President ,Clinical Development ,Main Board ,Stock Exchange ,Hong Kong Limited ,Cancer Center ,Database Syst ,Lancet Glob ,